Compare Citius Pharmaceuticals Inc (CTXR) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NetApp Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while NetApp Inc. trades at $160 (market cap $34.20B). The key difference: NetApp Inc. is far larger — about 2336.1× Citius Pharmaceuticals Inc's market cap, and NetApp Inc. pays a 1.19% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NTAP | |
|---|---|---|
Market Cap | $14.64M | $34.20B |
Sector | Health | Technology |
52-Week High | $1.82 | $181.08 |
52-Week Low | $0.53 | $94.11 |
Enterprise Value | $10.86M | $33.35B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
NetApp (NTAP) trades at $163.93, down 2.93% on the day, but maintains a bullish technical stance with strong moving averages and support near $162. The company demonstrates robust fundamentals with a 70.74% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.43 versus $2.27 expected. Recent news highlights AI-driven growth opportunities, such as StorageGRID 12.1 enhancements for AI workloads announced on June 23, 2026.
Outlook remains positive with analyst consensus target at $167.45, offering modest upside. Key opportunities include enterprise AI demand and all-flash storage adoption, while risks involve competitive pressures and debt levels rising to 29.89% of assets. The stock's valuation at a P/E of 25.82 warrants monitoring amid sector comparisons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
